Navigation Links
FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
Date:9/20/2007

king statements, including statements about the regulatory plans and timing for, and the expansion of, the Campath product label into earlier-line CLL, high-risk CLL, and combination and consolidation therapy. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others: the actual efficacy and safety of Campath in these indications; the actual timing and content of submissions to and decisions made by the U.S. Food and Drug Administration and other regulatory authorities, and the other risks and uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation the information under the heading "Risk Factors" in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of the Genzyme Quarterly Report on Form 10-Q for the quarter ending June 30, 2007. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and Genzyme undertakes no obligation to update or revise the statements.

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our annual and interim reports to the Frankfurt Stock Exchange and in our reports filed with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to
'/>"/>

SOURCE Genzyme Corp. and Bayer HealthCare Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. UW-Madison approves new research institute
2. FDA approves GEs heart-imaging technology
3. Senate approves bill to expand stem cell funding
4. FDA approves advanced digital mammography system
5. Building commission approves Institutes for Discovery
6. UW Board of Regents approves $134 million medical research facility
7. FDA approves Bone Cares Hectorol for treatment of kidney disease
8. New Microarray Labeling Kit for Preparing cDNA Probes
9. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
10. aRNA Synthesis and Labeling for Array Analysis
11. Amino Allyl Labeling for Array Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... announced that management will present a company overview at the ... a.m. ET in Boston, MA. ... on the "Investors & Media" section of the Company,s website, ... Isis website within 48 hours and will be archived for ...
(Date:10/30/2014)... 30, 2014  Regado Biosciences, Inc. (Nasdaq: ... conference call and live audio webcast on Thursday, November ... third quarter 2014 financial results. Interested participants ... (888) 347-1165 for domestic callers or (412) 902-4276 for ... under the investor relations section of the Regado website ...
(Date:10/30/2014)... DENVER (Oct. 29, 2014) – The severe flooding that ... have been less destructive if the bridges, roads and ... a new study from the University of Colorado Denver. ... of infrastructure," said Jimmy Kim, PhD, associate professor of ... and Applied Science and lead author the study. "There ...
(Date:10/27/2014)... 2014 The new research report, ... & Medium), Sub-type (Primary & Secondary), and End-User ... Transportation & Power Generation) - Trends and Forecasts ... with analysis and forecasting of the market size. ... with 52 Figures spread through 146 Pages and ...
Breaking Biology Technology:Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Regado Biosciences to Provide Third Quarter 2014 Financial Results 2CU Denver study says upgrading infrastructure could reduce flood damage 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4
... HILL, N.C., Jan. 12, 2011 Cempra Pharmaceuticals ... of solithromycin (CEM-101), the first fluoroketolide antibiotic, at ... Advanced Research and Development Authority (BARDA) industry day ...   Solithromycin is a clinical-stage fluoroketolide ...
... Jan. 11, 2011 Fred Hutchinson Cancer Research Center ... Robert Eisenman, Ph.D., a molecular biologist and geneticist, have ... Advancement of Science, or AAAS. Election as a fellow ... peers. Brent, a member of the Hutchinson ...
... 2011 Regenicin, Inc. (OTC Bulletin Board: ... of regenerative cell therapies to restore the health of ... annual OneMedForum at the Sir Francis Drake Hotel in ... McCoy, will present Regenicin,s core business model and strategic ...
Cached Biology Technology:Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (CEM-101) at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day 2Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (CEM-101) at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day 3Roger Brent and Robert Eisenman Named AAAS Fellows 2Roger Brent and Robert Eisenman Named AAAS Fellows 3Regenicin CEO to Participate in Live Webcast at OneMedForum Business Development and Finance Conference, January 11th at 4:00 PM PST 2
(Date:10/29/2014)... . Meiosis ... at the Max F. Perutz Laboratories (MFPL) of the ... dived into the process of meiosis in specific plant ... of the standard meiotic phases. The researchers describe the ... . , Meiosis is the two-step series of cell ...
(Date:10/29/2014)... of the Barcode of Life Data Systems ... Biodiversity Data Journal (BDJ) used specimen records ... into a human-readable text developed in manuscript within the ... to study the species distributions of ten Nearctic species ... is originally designed to support the generation and application ...
(Date:10/29/2014)... organisms in the living world compete with members ... in how much they invest into their competitive ... to get access to high-quality resources, while others ... of the lower-quality resources that are left over ... animal and human societies seems to fluctuate considerably ...
Breaking Biology News(10 mins):Meiotic cell division 'the other way round' 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Evolution of competitiveness 2Evolution of competitiveness 3
... Many plants produce toxic chemicals to protect themselves ... flower structures that prevent pollinators such as bees from ... evidence that flowering plants might also use chemical defences ... are published next week in the British Ecological Society,s ...
... MA - It is estimated that up to 10 ... of renal disease, with 450,000 patients with end stage ... Women,s Hospital, Massachusetts General Hospital and the University of ... be transplanted from one fish to another to regenerate ...
... students to ultimately provide quality patient care medical schools should ... the core disciplines of medicine, according to a study in ... College of Radiology ( www.jacr.org ). Physiology is the ... is vital that medical schools provide first-rate physiology education for ...
Cached Biology News:Secret life of bees now a little less secret 2Researchers unlock the potential for exploring kidney regeneration 2